Objective: To examine differences in the presentation and management of concussion in younger children (aged 4-8 years) versus preadolescents (9-12 years) and identify factors that influence recovery time.
Design: Retrospective analysis of prospectively collected data.
Setting: Pediatric sports medicine and orthopedics clinic.
Evidence-based insertion and maintenance bundles are effective in reducing the incidence of central line-associated bloodstream infections (CLABSI) in intensive care unit (ICU) settings. We studied the adoption and compliance of CLABSI prevention bundle programs and CLABSI rates in ICUs in a large network of acute care hospitals across Canada.
View Article and Find Full Text PDFAs a result of the COVID-19 pandemic, yoga classes have increasingly been delivered in virtual formats via online videoconferencing. Virtual reality (VR) guided meditations have been found to be a satisfactory means of teaching meditation, but satisfaction with practicing yoga in VR has not been researched. The present study evaluated whether participants experience a greater sense of presence and satisfaction with yoga instruction provided through 360-degree videos when the videos are viewed in three dimensions through a VR headset compared to a standard two-dimensional display.
View Article and Find Full Text PDF: Hyperkinetic movement disorders involve excessive, involuntary movements such as ataxia, chorea, dystonia, myoclonus, tics, and tremor. Recent advances in artificial intelligence (AI) allow investigators to integrate multimodal instrumented movement measurements and imaging techniques and to analyze these data together at scale. In this systematic review, we aim to characterize AI's performance in diagnosing and quantitatively phenotyping these disorders.
View Article and Find Full Text PDFAnemia is a common and progressive clinical manifestation of myelofibrosis that may occur as part of the disease pathogenesis as well as due to the myelosuppressive effects of some treatments, with a substantial impact on quality of life, prognosis, and healthcare resource utilization. Despite these burdens, anemia management has traditionally been a secondary priority to spleen and symptom control, due in part to the limitations of available therapeutic approaches. With the initial regulatory approvals of momelotinib, a Janus kinase 1 (JAK1), JAK2, and activin A receptor type 1 inhibitor that provides anemia-related benefits in addition to addressing splenomegaly and symptoms, re-evaluation of anemia as an early and prominent treatment consideration is warranted.
View Article and Find Full Text PDF